{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:57:14Z","timestamp":1762865834202},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gynecologic Oncology Group Statistical and Data Center","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.ygyno.2011.07.016","type":"journal-article","created":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T16:25:24Z","timestamp":1312561524000},"page":"182-186","source":"Crossref","is-referenced-by-count":13,"title":["Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A gynecologic oncology group study"],"prefix":"10.1016","volume":"123","author":[{"given":"Don S.","family":"Dizon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Gould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Diane","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"DeBernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric L.","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda R.","family":"Duska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula M.","family":"Fracasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.07.016_bb0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/PPO.0b013e318163c2e0","article-title":"Intraperitoneal chemotherapy in ovarian cancer: an update","volume":"14","author":"Runowicz","year":"2008","journal-title":"Cancer J"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0015","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a gynecologic oncology group study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2006.07.3494","article-title":"Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a gynecologic oncology group study","volume":"25","author":"Wenzel","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.410350310","article-title":"Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies","volume":"35","author":"Chaudhry","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0045","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.1997.15.5.1965","article-title":"Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting","volume":"15","author":"Gordon","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0050","first-page":"235","article-title":"IP cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the IV route","volume":"67","author":"Casper","year":"1983","journal-title":"Cancer Treat Rep"},{"issue":"4 Suppl","key":"10.1016\/j.ygyno.2011.07.016_bb0055","first-page":"1218","article-title":"Clinical pharmacology of cisplatin after intraperitoneal administration in patients with malignant ascites","volume":"1","author":"Fracasso","year":"1989","journal-title":"J Chemother"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0090-8258(85)90118-0","article-title":"Clinical pharmacology of intraperitoneal cisplatin","volume":"20","author":"Lopez","year":"1985","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2307\/2529393","article-title":"Multiple-stage procedures for drug screening","volume":"29","author":"Schultz","year":"1973","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1634\/theoncologist.7-5-437","article-title":"CA125 response: can it replace the traditional response criteria in ovarian cancer?","volume":"7","author":"Guppy","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2011.07.016_bb0090","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2010.12.358","article-title":"A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study","volume":"121","author":"Morgan","year":"2011","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581100566X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581100566X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T20:38:44Z","timestamp":1560458324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581100566X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S009082581100566X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.07.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}